tbuckley/cabot-search huggingface dataset:
Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient
Authors: Nathalie Chavarot, Carole Burger, Claire Aguilar, Anne Scemla, Rebecca Sberro-Soussan, Lucile Amrouche, Marianne Leruez-Ville, Frank Martinez, Christophe Legendre, Dany Anglicheau, Julien Zuber
Journal: Kidney International (2021)
AB0552 CHARACTERISTICS OF MYOSITIS SPECTRUM DISEASE - RHEUMATOID ARTHRITIS OVERLAP CASES IN A HUNGARIAN COHORT
Authors: L. Bodoki, Z. Griger, M. Nagy-Vincze, Z. E. Betteridge, K. Dankó
Journal: Annals of the Rheumatic Diseases (2020)

Background: Overlap syndromes are autoimmune disorders in which classification criteria of at least two connective tissue diseases (CTDs) are fulfilled. The Division of Clinical Immunology in Debrecen, Hungary oversees patients with idiopathic inflammatory myopathies (IIMs) since the 1980’s. Objectives: In a work called The Myositis Antibody Research Project, which is coordinated together with the Bath Institute for Rheumatic Diseases (UK), authors investigated 330 patients with myositis, all treated in this Hungarian center. Methods: The aim of this retrospective study was to investigate the frequency, clinical and serological parameters and therapeutic options in myositis – rheumatoid arthritis overlap cases in this group of 330 patients. Results: The frequency of overlap cases, as seen in literature, was 13.64%. The importance of myositis-associated antibodies (MAAs) can be seen on this results: 44.44% of overlap patients, while only 7.02% of not overlap patients were MAA positive. Out of our 45 overlap patients twenty-seven myositis - RA overlap patients could be identified. Among these 27 patients the women:men ratio was 12.5:1, PM:DM ratio was 2.375:1. Muscle weakness and sceletal involvement was present in every patient, myalgia in 77.78% and Raynaud’s phenomenon in 48.15% of the patients; general symptoms during disease relapse (fatigue, weight loss, fever) were present in 59.26%, 18.52% and 14.82%, respectively. Ten cases had seropositive rheumatoid arthritis, with high titer of rheumatoid factor. Authors underline the importance of lung involvement as internal organ manifestation: 8 patients had anti-synthetase antibodies (six anti-Jo-1, one anti-PL-7 and one anti-PL-12). In anti-PL-7 and anti-PL-12 positive patients interstitial lung disease (ILD) appeared some years before myositis and early agressive management of ILD resulted in fast remission of muscle weakness. Anti-Mi-2 and anti-SRP could be detected in two patients. Most frequent used disease modifying antirheumatic drugs were cyclophosphamide, methotrexate and cyclosporine, 19 patients received DMARD combination therapy. Biological therapy was used in 3 patients, intravenous or subcutaneous immuneglobulin in 4 patients and one patient with RA – myositis – antiphospholipid syndrome died because of asipartion pneumonia. Conclusion: Authors conclude that it is really challenging to treat these overlap cases: they form a very heterogenous group of patients and management has to be personalized. Disclosure of Interests: None declared
Covid-19: Sore throat, fatigue, and myalgia are more common with new UK variant
Authors: Elisabeth Mahase
Journal: BMJ (2021)

Covid-19: Sore throat, fatigue, and myalgia are more common with new UK variant Elisabeth MahasePeople infected with the new variant of covid-19 discovered in the South East of England (known as B.1.1.7 or VUI 202012/01) are more likely to have a cough, sore throat, fatigue, or myalgia than those infected with other variants, the Office for National Statistics has reported. 1
THU0032 The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity
Authors: A Kessel, E Toubi, G Grushko, E Sabo, M Rozenbaum, I Rosner
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Matrix metalloproteinase 3 (MMP-3) is reported to play an important role in the pathogenesis of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). Studies have also investigated the association of different tissue inhibitors of MMPs (TIMPs) with fibrosis in scleroderma (SSc). <h3>Objectives</h3> To evaluate the correlation of serum MMP-1,3 and TIMP-1 with severity and disease specific markers of SSC and RA. <h3>Methods</h3> Serum MMP-1,3 and TIMP-1 were measured in 42 SSc patients (age range 28–68 y, mean 47 y) and compared to measurement in 29 RA and healthy age/sex individuals. Elevated values of MMPs and TIMP-1 were defined as those greater than 2 S. D above normal mean. All SSc and RA patients were scored for disease severity. <h3>Results</h3> Serum MMP-1 was significantly elevated in 8/42 (19%) SSc patients (p = 0.01) but only in 2/29 (7%) RA patients (p = 0.2). Whereas MMP-3 levels were elevated in 10/29 (34%) RA patients (p = 0.002), it was elevated in only 5/42 (12%) SSc patients (0.03). TIMP-1 was found elevated in 17/42 (40%) SSc patients (p = 0.001) and in only 4/29 RA patients (a strong trend towards significance p = 0.052). We found a significant association between the elevation of both MMPs and TIMP-1 levels, with the severity of SSc. Those who had an increase of more than one MMP and/or TIMP, demonstrated life-threatening major organ involvement such as severe lung fibrosis, diffuse GI, or kidney involvement and severe cardiac failure. Contrary to that in SSc, the severity of RA was associated with MMP-3 only. <h3>Conclusion</h3> We confirm previous observations that MMPs and TIMPs may play an important role in various rheumatic diseases. Whereas serum increase of MMP-3 correlated with RA severity, SSc severity was characterised mainly by the increase of both MMP-1 and TIMP-1. This suggests that the MMPs and TIMPs involved in SSc are different than those playing a role in RA. These factors may play a synergistic role in the severity ofsystemic sclerosis.
AB1225 LIPID PROFILE COMPARISON IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: A CASE-CONTROL STUDY
Authors: D. Á. Galarza-Delgado, J. R. Azpiri-López, I. J. Colunga-Pedraza, A. Pérez Villar, I. C. Zárate Salinas, P. F. Frausto Lerma, M. A. Reyes Soto, D. E. Flores Alvarado, O. Ilizaliturri Guerra
Journal: Annals of the Rheumatic Diseases (2020)

Background: Rheumatoid arthritis (RA) and psoriasic arthritis (PsA) are autoimmune diseases, in both diseases it has been described that the main cause of morbidity and mortality is cardiovascular (CV) disease. Dyslipidemia is the most recognized CV risk factor. An association is recognized between the concentrations of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total triglycerides (TG), atherogenic index (AI) and the risk of myocardial infarction (MI), stroke and fatal cardiovascular disease (CVD). The relationship between serum lipid levels and CVD risk is potentially paradoxical in RA but this relationship has not been clarified in PsA. Objectives: To compare lipid profile between groups with RA, PsA and controls. Methods: A cross-sectional observational study was designed, which included 95 patients between 45-75 years who fulfilled the CASPAR classification criteria for PsA. 95 patients between 45-75 years who fulfilled the ACR / EULAR 2010 classification criteria for RA and 95 age-matched controls. Concentrations of CT, HDL-C, LDL-C, TG and atherogenic index were compared between the groups. Clinical measures were compared using one-way ANOVA or Kruskall-Wallis tests. Post-hoc analysis was performed with Bonferroni’s correction. A p ≤ 0.05 was considered statistically significant. The data was analyzed using the SPSS version 25 software package. Results: In our study, no significant difference in LDL-C was found between RA and PsA, however post-hoc analysis was performed where we found higher LDL-C levels among RA patients compared with controls ( p 0.025). RA patients had higher HDL-C than PsA patients ( p 0.006) but PsA had a higher HDL-C than controls ( p 0.007). TC/HDL-C was higher in PsA than RA and controls ( p 0.050). PsA patients were the group with the lowest HDL-C levels ( p 0.007). In contrast RA were the groups with the highest HDL-C levels ( p 0.007). (Table 1). Table 1. Clinical parameters. PARAMETER RA PsA Controls p TC* 176.6 ± 37.2 176.3 ± 35.9 186.34 ± 33.172 0.089 TG** 132.7 (102.0-187.3) 131.0 (97.2-189.2) 118.35(88.2-162.25) 0.245 HDL-C** 50.7 (42.1-62.6) 46.7 (37.4-53.9) 51.7 (41.3-60) 0.007 LDL-C* 94.36 ± 21.70 97.71 ± 30.12 105.32 ±31.35 0.025 TC/HDL-C** 3.41 (2.81-4.08) 3.74 (3.17-4.47) 3.49 (2.99-4.52) 0.050 *Data are reported in mean ± SD **Data is reported in median (IQR) Conclusion: Patients with inflammatory joint diseases have more adverse lipid profiles than controls. References: [1]Pietrzak, A., Chabros, P., Grywalska, E., Kiciński, P., Pietrzak-Franciszkiewicz, K., Krasowska, D., &amp; Kandzierski, G. (2019). Serum lipid metabolism in psoriasis and psoriatic arthritis–an update. Archives of medical science: AMS, 15(2), 369. Disclosure of Interests: None declared
SAT0178 Vertebral deformities in 229 female ra patients associations with clinical and demographical variables
Authors: RE Orstavik, G Haugeberg, TK Kvien, F Lilleaas, A Hoiseth
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To examine the frequency of vertebral deformities in a population based cohort of female rheumatoid arthritis (RA) patients, and their relationship with bone mineral density (BMD) and demographic and clinical variables. <h3>Methods</h3> Lateral radiographs of the spine were obtained from 229 female RA patients born 1926 or later (mean age (SD) 63.4 (6.7) yrs, mean disease duration 16.8 (10.4) yrs), recruited from a population based county RA register. Demographic and clinical variables were collected according to standardised procedures. Vertebral deformities were measured using a standardised semiquantitative method described by Genant, by an experienced radiologist (AH). Deformities were classified as mild, moderate or severe (a reduction in any of the vertebral heights of 20–25%, 25–40% and more than 40%, respectively). The patients underwent BMD measurements by DEXA of the femoral neck, total hip and lumbar spine (L2-L4) (Lunar Expert). T-scores were computed as provided from the manufacturer. <h3>Results</h3> The total number of deformities was 168 (87 moderate or severe). Forty-nine (21.4%) of the patients had at least two mild deformities or one moderate/severe deformity. Mean BMD (SD) for femoral neck was 0,806 gm/cm<sup>2</sup> (0.152), total hip 0.836 gm/cm<sup>2</sup> (0.158) and L2-L4 1,053 gm/cm<sup>2</sup> (0,201). In bivariate analysis, vertebral deformities were associated with age, ESR, number of deformed joints, previous non-vertebral fracture, long-term corticosteroid use and with BMD at all three measurement sites (p &lt; 0.05 for all variables). In logistic regression analysis, VD was independently associated with age, long-term corticosteroid use and with low bone mass at the hip. <h3>Conclusion</h3> This study indicates that several factors are independently related to vertebral deformities in RA, and should be considered when trying to identify patients with this complication. Physicians should probably be especially aware of vertebral deformities in patients with a history of non-vertebral fractures and long-term corticosteroid use.
Abstract 14660: Rivaroxaban Plus Aspirin versus With Aspirin in Patients With Prior Percutaneous Coronary Intervention (PCI): Insights From the COMPASS Trial
Authors: Kevin R Bainey, Scott Berkowitz, Deepak L Bhatt, John W Eikelboom, Keith A Fox, Basil S Lewis, Tamara Marsden, Eva Muehlhofer, Dragos Vinereanu, Petr Widimsky, Robert C Welsh
Journal: Circulation (2019)

Background: The COMPASS trial demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5mg twice-daily plus aspirin (ASA) 100mg once-daily vs ASA 100 mg once-daily reduced cardiovascular ...
The Cardiovascular Effects of Energy Drinks
Authors: Cetin Sanlialp Sara
Journal: Clinical Cardiology and Cardiovascular Interventions (2020)

Energy drinks are generally consumed by young people to increase athletic performance and concentration. Energy drinks contain high concentrations of caffeine, sugar, vitamin B complex, taurine, ginseng and guarana. There are not enough studies on these stimulants but past case-reports and small studies about energy drinks have been associated with cardiovascular complications. Especially with the use of alcohol or abuse drugs increase their undesirable effects and it may lead to cardiac morbidity and mortality. In this review, we aimed to focus on the effects and complications of energy drinks on the cardiovascular system.
CC17 group B Streptococcus exploits integrins for neonatal meningitis development
Authors: Romain Deshayes de Cambronne, Agnès Fouet, Amandine Picart, Anne-Sophie Bourrel, Cyril Anjou, Guillaume Bouvier, Cristina Candeias, Abdelouhab Bouaboud, Lionel Costa, Anne-Cécile Boulay, Martine Cohen-Salmon, Isabelle Plu, Caroline Rambaud, Eva Faurobert, Corinne Albigès-Rizo, Asmaa Tazi, Claire Poyart, Julie Guignot
Journal: Journal of Clinical Investigation (2021)

Group B Streptococcus (GBS) is the major cause of human neonatal infections. A single clone, designated CC17-GBS, accounts for more than 80% of meningitis cases, the most severe form of the infection. However, the events allowing blood-borne GBS to penetrate the brain remain largely elusive. In this study, we identified the host transmembrane receptors α5β1 and αvβ3 integrins as the ligands of Srr2, a major CC17-GBS-specific adhesin. Two motifs located in the binding region of Srr2 were responsible for the interaction between CC17-GBS and these integrins. We demonstrated in a blood-brain-barrier cellular model that both integrins contributed to the adhesion and internalization of CC17-GBS. Strikingly, both integrins were overexpressed during the postnatal period in the brain vessels of the blood-brain barrier and blood-cerebrospinal fluid barrier and contributed to juvenile susceptibility to CC17 meningitis. Finally, blocking these integrins decreased the ability of CC17-GBS to cross into the CNS of juvenile mice in an in vivo model of meningitis. Our study demonstrated that CC17-GBS exploits integrins in order to cross the brain vessels, leading to meningitis. Importantly, it provides host molecular insights into neonate's susceptibility to CC17-GBS meningitis, thereby opening new perspectives for therapeutic and prevention strategies of GBS-elicited meningitis.
Consultant is struck off after pressuring two patients to remove unfavourable online reviews
Authors: Clare Dyer
Journal: BMJ (2021)

A consultant who worked as an ear, nose, and throat surgeon in the NHS has been struck off the UK medical register for “a pattern of failures” in private cosmetic rhinoplasty work he performed on six patients more than four years ago and for pressuring two of them to remove unfavourable online reviews of his work.

A medical practitioners tribunal found that Mohammed Tahery misled some of the patients during the consent process about the rate of revision surgery needed after his rhinoplasty operations, claiming it was rare when the true rate was 20-25%. In one patient’s case, Tahery’s surgical work was …
Abstract 13747: Addition of Dipeptdyl Peptidase-4 Inhibition to Metformin Mono-therapy Reduces Vascular Inflammation in Humans With Diabetes Mellitus Type 2
Authors: Venkata K Puppala, Amberly Branum, Shahreyar Muhammad, Jingli Wang, Rong Ying, Michael Tanner, Michael Widlansky
Journal: Circulation (2016)

Introduction: Endothelial dysfunction precedes the development of atherosclerosis and predicts future adverse cardiovascular events. Systemic endothelial dysfunction is well described in patients with type 2 diabetes (T2DM). Glycemic control that also favorably impacts the vascular endothelium would be an ideal choice for T2DM patients. Prior cell culture and animal work on dipeptdyl peptidase-4 (DPP-4) inhibition suggest these agents could favorably impact human endothelial function. In our study, we looked at the effect of sitagliptin (a DPP4 inhibitor) on endothelial function in T2DM patients on stable metformin therapy. Methods: Thirty-eight subjects with T2DM who were on a stable dose of metformin were enrolled in a double-blind cross-over trial of sitagliptin (100 mg/day) for eight weeks versus matching placebo. Endothelium dependent vasodilation was measured by percent flow mediated dilatation (FMD) of the brachial artery 2 hours after the 1st dose of sitaglitin and placebo and following 8 weeks of sitagliptin and placebo administration. A 4 week washout period was interposed between treatment periods. Plasma markers for endothelial cell activation, intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1) were also measured following chronic dosing of sitagliptin and placebo. Results: FMD% was not significantly different across all time points (5.6±2.3% pre-sitagliptin 6.3±2.4 post acute sitagliptin, 5.8±2.3 post chronic sitagliptin, 5.2±1.8 pre-placebo, 5.6±2.1 post acute placebo, 6.0±2.9 post chronic placebo, P=0.31 by repeated measures ANOVA). No differences were noted in the hyperemic flow responses as well (P=0.26). Plasma ICAM-1 ( endothelial cell activation ICAM) levels were significantly lower following 8 weeks of sitagliptin compared to placebo [192±70 vs. 228±73 ng/mL (P&lt;0.0001)]. Plasma VCAM-1 was not significantly different following 8 weeks of each treatment [(520±155 vs. 620±96 ng/mL (P=0.67)]. Conclusions: While the addition of DPP-4 inhibition with sitagliptin did not alter endothelium-dependent vasodilation in humans with T2DM on metformin therapy, vascular inflammation may be reduced which could provide an added benefit to these patients.
HP0035 Association between tess functional questionnaire and timed tests of function
Authors: KL Barker, SE Lamb, AH Simpson
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> It is important to evaluate the functional result of any orthopaedic intervention. This is commonly achieved by completing tests which evaluate function in a controlled environment under a specific set of conditions, allowing objective measures to be gathered. Alternatively patient-reported assessments may be used, which reveal the limitations that the patients experience when carrying out everyday activities in their own environment. This study investigated the association between these two methods. <h3>Method</h3> 40 adult patients undergoing lower limb reconstruction surgery completed the Toronto Extremity Salvage Score (TESS) pre-operatively and at 6, 12 and 24 months post surgery. TESS evaluates a single domain, physical disability, based on patients' reports of their function. It is applicable to a heterogeneous population being sensitive to change across a range of levels of disability.<sup>1</sup> They also performed 3 timed tests of stair climbing, sit-to-stand and walking. <h3>Results</h3> Within subjects changes were analysed using the Wicoxon matched-pairs test and associations between variables by a Spearman's Rank Correlation Coefficient. Subjects, on average, improved on all of the functional measures, with significant improvements from the baseline score at 12 and 24 months (P &lt; 0.001). Changes at 6 months were not significant. There was a poor correlation between TESS and the timed function tests. To explore this further the association between specific questions in TESS and the objective performance tests were tested. This showed significant correlations between walking speed and the question about walking indoors (0.53, P &lt; 0.003), between stair climbing and the question about going upstairs (0.64, P &lt; 0.001) and downstairs (0.42, P &lt; 0.025) and sit-to-stand and the question about getting out of a chair (0.41, P &lt; 0.03). <h3>Conclusions</h3> The association between the self-reported and observed outcome measures was not as strong as may have been expected when both purport to measure the same dimension of physical function. One explanation for this may be that the observed outcomes were all timed activities and patients' satisfaction with their functional abilities may not be related to time. Whilst timed tests may be reliable tests of function, they may not be as valid or useful a measure as patient-reported measures. <h3>Reference</h3> Davis AM, Bell RS, Badley EM, <i>et al</i>. Evaluating functional outcome in patients with lower extremity sarcoma. Clin Orthop Relat Res. 1999;358:90–100
CKAP2L Promotes Non–Small Cell Lung Cancer Progression through Regulation of Transcription Elongation
Authors: Tiziana Monteverde, Sudhakar Sahoo, Manuela La Montagna, Peter Magee, Lei Shi, Dave Lee, Robert Sellers, Alexander R. Baker, Hui Sun Leong, Matteo Fassan, Michela Garofalo
Journal: Cancer Research (2021)

Abstract Chromosomal instability (CIN) is a driver of clonal diversification and intratumor heterogeneity, providing genetic diversity that contributes to tumor progression. It is estimated that approximately 80% of solid cancers, including non–small cell lung cancer (NSCLC), exhibit features of CIN, which affects tumor growth and response to therapy. However, the molecular mechanisms connecting CIN to tumor progression are still poorly understood. Through an RNAi screen performed on genes involved in CIN and overexpressed in human lung adenocarcinoma samples, we identified the cytoskeleton-associated protein 2-like (CKAP2L) as a potential oncogene that promotes lung cancer proliferation and growth in vitro and in vivo. Mechanistically, CKAP2L directly interacted with RNA Pol II and regulated transcription elongation of key genes involved in spindle assembly checkpoint, chromosome segregation, cell cycle, and E2F signaling. Furthermore, depletion of CKAP2L increased the sensitivity of NSCLC cells to alvocidib, a pan-CDK inhibitor, leading to a significant reduction of cell proliferation and an increase in cell death. Altogether, these findings shed light on the molecular mechanisms through which CKAP2L, a protein involved in CIN, promotes cancer progression and suggest that its inhibition represents a novel therapeutic strategy in NSCLC. Significance: These findings demonstrate the oncogenic function of CKAP2L through regulation of transcription elongation and suggest that targeting CKAP2L could enhance therapeutic response in patients with NSCLC.
Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study
Authors: K.M.A. Endre, L. Landrø, M. LeBlanc, P. Gjersvik, K.C. Lødrup Carlsen, G. Haugen, G. Hedlin, C.M. Jonassen, B. Nordlund, K. Rudi, H.O. Skjerven, A.C. Staff, C. Söderhäll, R. Vettukattil, E.M. Rehbinder
Journal: British Journal of Dermatology (2021)

Diagnosing atopic dermatitis (AD) in infants is challenging.To determine the incidence and persistence of eczema and AD in infants using the UK Working Party (UKWP) and Hanifin and Rajka (H&R) criteria.A cohort of 1834 infants was examined clinically at 3, 6 and 12 months of age. AD was diagnosed by UKWP (3, 6 and 12 months) and H&R (12 months) criteria. Logistic regression models were used to assess the relationship between AD and eczema.Eczema was observed in 628 (34·2%) infants (n = 240, n = 359 and n = 329 at 3, 6 and 12 months, respectively), with AD diagnosed in 212 (33·7%) infants with any eczema and in 64/78 (82%) infants with eczema at all three visits. The odds of AD were lower with first presentation of eczema at 6 [odds ratio (OR) 0·33, 95% confidence interval (CI) 0·22-0·48] or 12 months (OR 0·49, 95% CI 0·32-0·74) than at 3 months, and higher in infants with eczema at three (OR 23·1, 95% CI 12·3-43·6) or two (OR 6·5, 95% CI 4·3-9·9) visits vs. one visit only. At 12 months, 156/329 (47·4%) fulfilled the UKWP and/or H&R criteria; 27 (8%) fulfilled the UKWP criteria only and 65 (20%) only the H&R criteria. Of the 129 infants who fulfilled the H&R criteria, 44 (34·1%) did not meet the itch criterion.Used in combination and at multiple timepoints, the UKWP and H&R criteria for AD may be useful in clinical research but may have limited value in most other clinical settings.